Search results for "hazard"

showing 10 items of 1517 documents

Second Malignancies Following Childhood Cancer Treatment in Germany From 1980 to 2014.

2018

BACKGROUND Because of improvements in cancer treatment, more than 80% of all children with cancer now survive at least five years from the time of diagnosis. As a result, late sequelae of cancer and its treatment have become more common, particularly second malignancies. We studied the current incidence of second malignancies among childhood cancer survivors in Germany. METHODS This study is based on the cohort of the German Childhood Cancer Registry (Deutsches Kinderkrebsregister, DKKR). Persons given the diagnosis of a first malignancy at any time in the years 1980-2014 who were no more than 14 years old at the time of diagnosis and survived at least six months thereafter were included in…

AdultMalePediatricsmedicine.medical_specialtyPopulationMalignancy03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsRisk FactorsGermanymedicineHumansCumulative incidence030212 general & internal medicineRegistrieseducationChildProportional Hazards Modelseducation.field_of_studyChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceHazard ratioCancerNeoplasms Second PrimaryGeneral MedicineMiddle Agedmedicine.diseaseAdult Survivors of Child Adverse Events030220 oncology & carcinogenesisCohortFemaleOriginal ArticlebusinessDeutsches Arzteblatt international
researchProduct

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients

2012

Three hundred and twenty-seven patients from two population-based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors for survival and leukaemia in a long-term survey. The relative survival (RS) was 72% and 46% at 10 and 20 years respectively, from the time of diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 10(9) /l and thrombo-embolism at diagnosis as independent risk factors. Patients with two or three of these factors had a 10 year RS of 26%, compared with 59% and 84% in patients with one and no risk factors, respectively. Age and leucocyte count are the main predicting factors for survival in polycy…

AdultMalePolycythaemiamedicine.medical_specialtyLeukocytosisPopulationComorbidityKaplan-Meier EstimateLeukocyte CountYoung AdultPolycythemia veraRisk FactorsCause of DeathNeoplasmshemic and lymphatic diseasesWhite blood cellInternal medicineEpidemiologymedicineHumansRisk factoreducationPolycythemia VeraAgedProportional Hazards ModelsAged 80 and overHeart FailureSwedeneducation.field_of_studyRelative survivalProportional hazards modelbusiness.industryThrombosisHematologyMiddle AgedPrognosismedicine.diseaseSurgeryLeukemia Myeloid Acutemedicine.anatomical_structureDisease ProgressionFemaleFrancebusinessFollow-Up StudiesBritish Journal of Haematology
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer

2018

Aim The aim of this retrospective multicentre study was to evaluate the clinical and prognostic effect of fluorine-18-fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) in the restaging process of pancreatic cancer (PC). Materials and methods Data from patients treated for primary PC, who underwent18F-FDG-PET/CT for suspicious of disease progression, were collected. Accuracy was assessed employing conventional diagnostic procedures, multidisciplinary team case notes, further18F-FDG-PET/CT scans and/or follow-up. Receiver operating characteristic curve and likelihood ratio (LR+/-) analyses were used for completion of accuracy definition. Progression-free survival (PFS) and overall sur…

AdultMalePrognosioverall survival18F-FDG-PET/CTpancreatic cancer030218 nuclear medicine & medical imaging03 medical and health sciencesdisease progression0302 clinical medicineRetrospective StudieFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyPancreatic cancerrestagingHumansMedicineRadiology Nuclear Medicine and imagingProgression-free survivalRetrospective StudiesAgedNeoplasm StagingReceiver operating characteristicbusiness.industryProportional hazards modelHazard ratioPancreatic NeoplasmArea under the curveRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasms030220 oncology & carcinogenesisFemalebusinessNuclear medicineprogression-free survivalHumanNuclear Medicine Communications
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

Comparing asthma treatment in elderly versus younger patients

2011

SummaryA randomised 6-month study compared two maintenance doses of budesonide/formoterol (Symbicort® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2 and 2 × 2, in 8053 asthmatics with symptoms despite treatment with inhaled corticosteroids ± inhaled long-acting β2-agonists. This analysis compared response to the two treatments in elderly patients, ≥65 years, with that in younger patients. Elderly patients with early- or late-onset asthma were also compared.Elderly patients had lower post-bronchodilator FEV1 percentage predicted normal at base…

AdultMalePulmonary and Respiratory MedicineBudesonideSymbicort SMARTmedicine.medical_specialtylaw.inventionExacerbationsElderlyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansBudesonideBudesonide/formoterolAgedAsthmaACQDose-Response Relationship Drugbusiness.industryHazard ratiomedicine.diseaseConfidence intervalAsthmaBronchodilator AgentsSurgeryTreatment OutcomeBudesonide/formoterolEthanolaminesAsthma Control QuestionnaireDisease ProgressionQuality of LifeDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct

The Influence of the Primary Tumor on the Long-term Results of Pulmonary Metastasectomy for Metastatic Renal Cell Carcinoma

2011

OBJECTIVE To investigate one of the primary tumor (PT) on pulmonary metastasectomy (PM) for metastatic renal cell carcinoma (RCC) and to define prognostic factors. METHODS Retrospective review of patients with pulmonary metastases from RCC from January 1999 through December 2008 was performed. All patients underwent PM with curative intend. TNM-classification, tumor stage and PT grade, disease-free-interval (DFI) from nephrectomy to the diagnosis of metastasis, systemic chemotherapy before surgical intervention, surgical procedures, morbidity, mortality, and survival were investigated. RESULTS One-hundred seven consecutive patients (age 61.5 ± 9.6 years) underwent PM. Morbidity and mortalit…

AdultMalePulmonary and Respiratory MedicineOncologymedicine.medical_specialtyLung NeoplasmsTime Factorsmedicine.medical_treatmentUrologyKaplan-Meier EstimateNephrectomyRisk AssessmentRisk FactorsRenal cell carcinomaInternal medicinemedicineAdjuvant therapyHumansPneumonectomyCarcinoma Renal CellAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overUnivariate analysisProportional hazards modelbusiness.industryMortality rateMetastasectomyMiddle Agedmedicine.diseasePrimary tumorKidney NeoplasmsNeoadjuvant TherapyNephrectomyTreatment OutcomeChemotherapy AdjuvantLymphatic MetastasisMultivariate AnalysisFemaleSurgeryNeoplasm GradingMetastasectomyCardiology and Cardiovascular MedicinebusinessThe Thoracic and Cardiovascular Surgeon
researchProduct

Lack of association of Aspergillus colonization with the development of bronchiolitis obliterans syndrome in lung transplant recipients: An internati…

2019

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is a major limitation in the long-term survival of lung transplant recipients (LTRs). However, the risk factors in the development of BOS remain undetermined. We conducted an international cohort study of LTRs to assess whether Aspergillus colonization with large or small conidia is a risk factor for the development of BOS.METHODS: Consecutive LTRs from January 2005 to December 2008 were evaluated. Rates of BOS and associated risk factors were recorded at 4 years. International Society of Heart and Lung Transplantation criteria were used to define fungal and other infections. A Cox proportional-hazards-model was constructed to assess the a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentInternational Cooperationmedicine.medical_treatmentBronchiolitis obliterans030230 surgeryCohort StudiesYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLung transplantationBOSCumulative incidenceRisk factorBronchiolitis ObliteransTransplantationbusiness.industryHazard ratioMiddle Agedcolonizationmedicine.diseasehumanitiesBOS; aspergillus; colonization; lung transplantation; risk factorsTransplantationAspergillus030228 respiratory systemCohortFemaleSurgeryCardiology and Cardiovascular MedicinebusinessLung TransplantationCohort studyThe Journal of Heart and Lung Transplantation
researchProduct

Metastasectomy With Standardized Lymph Node Dissection for Metastatic Renal Cell Carcinoma: An 11-Year Single-Center Experience

2013

Background Pulmonary metastasectomy (PM) for metastatic renal cell carcinoma is an established method of treatment for selected patients. The incidence of intrathoracic lymph node metastases (ITLNM) and outcomes remain controversial. The purpose of this study was to determine the incidence of ITLNM and long-term outcome of PM for metastatic kidney cancer. Methods From January 1999 to December 2009, 116 patients (82 men, age 61.7 ± 9.0 years) with metastases from kidney cancer underwent PM and systematic lymph node dissection with curative intent. Kaplan-Meier analyses, log-rank test, and Cox regression analyses were used to estimate survival and to determine prognosticators of survival. Res…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentThoracic CavityKaplan-Meier EstimateYoung AdultRenal cell carcinomaGermanymedicineHumansCarcinoma Renal CellLymph nodeAgedProportional Hazards ModelsRetrospective StudiesAged 80 and overUnivariate analysisProportional hazards modelbusiness.industryMortality rateMetastasectomyMiddle Agedmedicine.diseaseKidney NeoplasmsIntrathoracic Lymph NodeSurgerySurvival Ratemedicine.anatomical_structureLymphatic MetastasisLymph Node ExcisionFemaleSurgeryMetastasectomyCardiology and Cardiovascular MedicinebusinessKidney cancerForecastingThe Annals of Thoracic Surgery
researchProduct

pT2 Adenocarcinoma of the Esophagus: Early or Advanced Cancer?

2013

Background There is an increasing trend to include patients with esophageal carcinoma invading the muscularis propria (pT2) in neoadjuvant therapy regimens. But it is unclear which patients have prognostic benefit from this strategy. The aim of this study was to assess the prognosis and prognostic factors in patients with pT2 esophageal adenocarcinoma to further optimize treatment strategies. Methods Included were patients with pT2 esophageal adenocarcinoma treated operatively at three centers specializing in upper gastrointestinal surgery. There were 159 patients (139 male) without induction therapy; median age was 64.5 years. Survival was analyzed by univariate and multivariate analysis. …

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaGastroenterologyInternal medicinemedicineCarcinomaHumansEsophagusLymph nodeSurvival rateNeoadjuvant therapyAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryHazard ratioMiddle AgedPrognosismedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureLymphatic MetastasisAdenocarcinomaFemaleSurgeryLymphCardiology and Cardiovascular MedicinebusinessThe Annals of Thoracic Surgery
researchProduct